No Data
Ocean Bio: Report for the third quarter of 2024
zhejiang dayang biotech group (003017.SZ) released its performance for the first three quarters, with a net income of 51.27 million yuan, a year-on-year increase of 27.60%.
Zhitoong Finance APP News, zhejiang dayang biotech group (003017.SZ) released the third quarter report of 2024, during the reporting period, the company achieved revenue...
zhejiang dayang biotech group (003017.SZ): plan to invest 0.302 billion yuan to build an annual production of 800 tons of ammeline hydrochloride relocation and expansion technical transformation project.
Zhejiang Dayang Biotech Group (003017.SZ) announced that on October 17, 2024, the company held the 20th meeting of the fifth board of directors to review and approve the proposal on investing in the construction of an annual output of 800 tons of amphotericin B hydrochloride relocation and expansion project. The board agreed to invest 0.3019 billion RMB of self-raised funds in the construction of the project. This is to further expand the operation scale of the company's flagship products, enhance product market competitiveness, and also respond to Jiande City's policy of replacing polluting industries with emerging ones and industrial transformation, by incorporating existing hazardous chemicals.
zhejiang dayang biotech group (003017.SZ) plans to invest 0.302 billion yuan to build a project for relocating and expanding the annual production of 800 tons of amine propanol chloride.
Zhītōng Cáijīn APP News, zhejiang dayang biotech group (003017.SZ) announced that the company plans to use self-raised funds of 0.302 billion yuan RMB (currency below...
Express News | Zhejiang Dayang Biotech Group: investing 0.302 billion yuan to build an annual output of 800 tons of amine propranolol hydrochloride relocation and expansion technological transformation project.
Zhejiang Dayang Biotech Group (003017.SZ): The employee stock ownership plan for 2024 has been completed without any trade transfers.
On September 10th, Gelunhui announced that on September 10th, 2024, the company received the "Confirmation of Securities Transfer Registration" issued by China Securities Depository and Clearing Corporation Limited, Shenzhen Branch. The 1,947,030 shares of the company's stocks held by the "Zhejiang Dayang Biotech Group Co., Ltd. Repurchase Special Securities Account" were transferred on September 9th, 2024 to the "Zhejiang Dayang Biotech Group Co., Ltd. - 2024 Employee Stock Ownership Plan" Account. The transferred shares account for 2.32% of the total share capital of the company. This employee stock ownership plan is completed through non-trading.
No Data
No Data